产品
编 号：F285638
分子式：C19H17F2N7O
分子量：397.38
分子式：C19H17F2N7O
分子量：397.38
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 233275-76-8
产品详情
生物活性：
MK0343 (MRK-409) is an orally bioavailable GABAA receptor subtype-selective partial agonist. MK0343 is a non-sedating anxiolytic.
体内研究：
MK0343 readily penetrates the brain in rats and occupies the benzodiazepine site of GABAA receptors, measured using an in vivo [3H]flumazenil binding assay, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL.Animal Model:Male Sprague-Dawley rats (approximately 250–300g) (pharmacokinetics)
Dosage:1, 2 or 3?mg/kg
Administration:Oral administration
Result:Readily penetrated the brain in rats and occupies the benzodiazepine site of GABAA receptors, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL.
MK0343 (MRK-409) is an orally bioavailable GABAA receptor subtype-selective partial agonist. MK0343 is a non-sedating anxiolytic.
体内研究：
MK0343 readily penetrates the brain in rats and occupies the benzodiazepine site of GABAA receptors, measured using an in vivo [3H]flumazenil binding assay, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL.Animal Model:Male Sprague-Dawley rats (approximately 250–300g) (pharmacokinetics)
Dosage:1, 2 or 3?mg/kg
Administration:Oral administration
Result:Readily penetrated the brain in rats and occupies the benzodiazepine site of GABAA receptors, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备